| Literature DB >> 35433613 |
Claudia Robbiati1, Maria Elena Tosti2, Giampaolo Mezzabotta1, Francesca Dal Maso3, Ofélia M Lulua Sachicola4, Paulo Siene Tienabe4, Joseph Nsuka4, Marco Simonelli2, Maria Grazia Dente2, Giovanni Putoto1.
Abstract
TB Programs should promote the use of digital health platforms, like Electronic Medical Records (EMR) to collect patients' information, thus reducing data incompleteness and low accuracy and eventually improving patients' care. Nevertheless, the potential of digital health systems remains largely unexploited in low-resource settings. Angola is one of the 14 countries with a triple burden of TB, TB/HIV and MDR-TB (multidrug-resistant TB) and it is among the three countries, together with Congo and Liberia that have never completed a drug-resistance survey so far. The Sanatorium Hospital of Luanda and the Tuberculosis Dispensary of Luanda are the two reference health facilities in Luanda dealing with most of the TB cases, and they both rely entirely on paper-based data collection. The aim of this paper is to describe a three-stage process for the development of a TB EMR system in these two health facilities of Luanda and to share the lessons learned. The description is focused on the activities that took place from March 2019 to January 2020. Main lessons learned were identified in the importance of engaging all the stakeholders in the development process, in the mainstream of the "think digital" transition, in the promotion of a monitoring and evaluation (M&E) culture and in the planning of the system's sustainability. This approach may be replicated in similar contexts where the development of a TB EMR system is sought, and the lessons learned could assist and facilitate the programming of the interventions.Entities:
Keywords: Angola; Electronic Medical Record (EMR); TB; quality; surveillance
Mesh:
Year: 2022 PMID: 35433613 PMCID: PMC9009439 DOI: 10.3389/fpubh.2022.745928
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
SWOT analysis.
|
|
|
|---|---|
| Key stakeholders' commitment to the EMR system development and implementation; | Suboptimal data collection and management, and ultimately patients' care; |
|
|
|
| Window for capacity building initiatives; | Disturbance of daily activities during the system roll-out; |
Examples of indicators of weaknesses in the current data collection system and the correspondent EMR system response.
|
|
|
|---|---|
| Lack of registration of the patients dismissed after the first visit because not considered suspect TB cases. The whole facility workload is therefore missing. | All the patients are registered at their 1st access to the health facility. |
| Use of multiple forms and codes for the same patient. | Univocal code, univocal record saved indefinitely and accessible from each established data collection point. |
| Delays and incompleteness of internal and external reports. | Specific reporting feature of the system to ensure delivering of internal and external reports in accordance with the requirements of the national reporting system. |
| Poor or inexistent data collection system at some cruxes of the patient's care pathway. | All the needed data collection points of the patient's care pathway are included as active units of the EMR system. |
| Data quality. | Guided choice, mandatory answers, improved M&E system. |
Enhanced TB medical record sections description.
|
|
|
|---|---|
| Patient registration and socio-demographic information. | All the patients are registered, also patients without clear TB symptoms. The registration also includes the attribution of a univocal patient number that will follow him/her throughout the clinical course. Socio-demographics data are collected. |
| Patient classification and clinical information. | Patient classification (new, retreatment, transferred) and related information is recorded, together with main TB symptoms, signs, risk factors (contact with a TB case, MDR-TB cases among the relatives, HIV infection and therapy, diabetes, pregnancy, smoke, alcohol) and body weight. |
| First medical consultation outcome. | Based on the clinical assessment and the evaluation of risk factors during the first visit, patients could be defined as ≪suspect TB case≫ and referred for diagnostic confirmation or hospitalization. |
| Diagnostic information (laboratory and radiology). | Results of bacilloscopy, GeneXpert, culture, antibiogram, RX, biopsy, HIV test, clinical biochemistry are reported. For the bacilloscopy, reasons for not performing the test need to be specified. |
| Case classification. | Following the diagnostic process, the TB diagnosis is confirmed or excluded. The TB case is further classified according to the pulmonary or extrapulmonary location and to the presence of HIV co-infection. Contacts of people living with the patient are recorded, to promote active case finding. |
| Treatment plan. | Type of treatment according to the national guidelines, dosage, starting and end date and observations are recorded. |
| Therapy follow-up. | Date, type and quantity of medications delivered to the patient along the course of treatment are recorded. Also, patient's eventual delay and reason, and treatment compliance are recorded, in order to determine the next date for the delivery of medications (this will be automatically calculated in the EMR system). |
| Follow-up consultations. | During follow-up consultations (2, 5, 6 months for drug-sensitive TB and every month for 20 months for MDR-TB), therapy compliance, symptoms, side effects, weight monitoring and observations are recorded. |
| Diagnostic follow-up (laboratory and radiology). | Follow-up results of diagnostic tests (bacilloscopy, GeneXpert, culture, antibiogram, RX, biopsy, HIV test, clinical biochemistry) are recorded. |
| Treatment outcome. | Treatment outcomes according to national guidelines are reported. |
Figure 1EMR system print screen.